Abstract
Background: Since the advent of 27-gauge microincision vitrectomy system a decade ago, evidence regarding the feasibility, safety, and effectiveness of 27-gauge pars plana vitrectomy (PPV) has increased.Aim: To assess the effectiveness and safety profile of 27-gauge PPV for various vitreoretinal conditions associated with uveitis.Methods: We retrospectively investigated 73 consecutive cases that underwent primary 27-gauge PPV for uveitis-related ocular disorders between October 2014 and April 2021. The primary outcome measures were mean change in logMAR best-corrected decimal visual acuity (BCVA) pre-operatively to 3 months post-operatively, the proportion of BCVA improvement category defined as the degree of logMAR BCVA difference (“improved” [≤−0.3], “unchanged” [−0.3 to 0.3], and “worsened” [≥0.3]) pre-operatively to 3 months post-operatively, the mean change in intraocular inflammation scores pre-operatively to 3 months post-operatively; and intraoperative and post-operative complications.Results: The mean logMAR BCVA significantly improved from 0.69 pre-operatively to 0.42 at 3 months post-operatively (P = 0.017). The percentages of eyes with “improved,” “unchanged,” and “worsened” BCVA at 3 months post-operatively were 37, 50, and 13%, respectively. The mean anterior chamber cell score was 0.6 pre-operatively and 0.2 at 3 months post-operatively (P = 0.001), the mean anterior chamber flare score was 0.4 pre-operatively and 0.1 at 3 months post-operatively (P = 0.004), and the mean vitreous haze score was 1.9 pre-operatively and 0.1 at 3 months post-operatively (P < 0.001). Surgery-related complications occurred in 35 (48%) eyes, 68% of which were related to intraocular pressure and transient.Conclusions: Given its risk–benefit profile, 27-gauge PPV is a promising option for the treatment of vitreoretinal disorders in uveitis.
Highlights
Medical therapy is the cornerstone for the management of uveitis, a potentially sight-threatening intraocular inflammatory disorder [1, 2]
Aim: To assess the effectiveness and safety profile of 27-gauge pars plana vitrectomy (PPV) for various vitreoretinal conditions associated with uveitis
Given its risk–benefit profile, 27-gauge PPV is a promising option for the treatment of vitreoretinal disorders in uveitis
Summary
Medical therapy is the cornerstone for the management of uveitis, a potentially sight-threatening intraocular inflammatory disorder [1, 2]. Pars plana vitrectomy (PPV) may be performed when medical therapy fails, secondary vitreoretinal complications develop, or diagnostic vitreous/retinal sampling is necessary [3,4,5,6,7,8,9,10,11,12]. The microincision vitrectomy system (MIVS), first appeared as 25-gauge PPV, was developed nearly two decades ago [16] and has gradually become the standard surgical platform for various indications, including uveitis-related vitreoretinal disorders [8, 9]. To address this research gap, this study aimed to assess the effectiveness and safety profile of 27-gauge PPV for various vitreoretinal conditions associated with uveitis. Since the advent of 27-gauge microincision vitrectomy system a decade ago, evidence regarding the feasibility, safety, and effectiveness of 27-gauge pars plana vitrectomy (PPV) has increased
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
